세계 고처리량 스크리닝(HTS) 시장 규모는 2024년 271억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 시장 규모가 507억 달러에 달하고, 2025-2033년 7.2%의 연평균 성장률(CAGR)을 보일 것으로 예측했습니다. 스크리닝 기술의 적용 증가는 시장 성장을 가속하는 주요 요인 중 일부입니다.
주요 시장 성장 촉진요인의약품 제조에 필요한 시간을 최소화하기 위해 HTS의 이용이 증가하고 있는 것이 주로 시장 성장을 가속하고 있습니다. 또한, 생명을 위협하는 다양한 질병의 치료용 신약 개발도 HTS 기술에 대한 수요를 자극하고 있습니다.
주요 시장 동향 : 인공지능(AI), 머신러닝(ML) 등 첨단 기술과 고처리량 스크리닝(HTS)의 통합을 통한 자동화 및 고속 데이터 처리의 촉진은 시장 성장을 증가시키는 중요한 트렌드 중 하나입니다.
지역별: 고처리량 스크리닝(HTS) 시장 예측 보고서에서는 지역별로 시장을 세분화하여 분석합니다. 여기에는 북미, 아시아태평양, 유럽, 라틴아메리카, 중동 및 아프리카가 포함됩니다. 북미는 고처리량 스크리닝(HTS) 채용 증가, R&D 비용 증가, 조합화학 및 유전체학 분야의 발전 등의 요인으로 인해 고처리량 스크리닝(HTS) 시장에서 큰 시장 점유율을 차지할 것으로 예측됩니다.
경쟁 구도: 고처리량 스크리닝(HTS) 시장의 주요 기업으로는 Agilent Technologies Inc. Laboratories Inc., Charles River Laboratories International Inc. Sygnature Discovery, Tecan Group Ltd., Thermo Fisher Scientific 등이 있습니다.
과제와 기회: 고처리량 스크리닝(HTS) 시장의 과제는 데이터 관리의 복잡성, 생리학적으로 더 적합한 분석 모델의 필요성 등이며, 기회는 자동화, 인공지능, 장기 칩 시스템과 같은 기술의 발전으로 보다 효율적이고 예측 가능한 스크리닝 프로세스를 위한 기술 발전이 있습니다.
HTS 시설 증가
생명을 위협하는 다양한 질병 치료를 위한 신약 개발이 시장 성장의 주요 원동력이 되고 있습니다. 또한, 의약품 제조에 필요한 시간을 단축하기 위한 HTS 활용 증가도 시장 성장에 기여하고 있습니다. 이와 더불어, 고처리량 스크리닝(HTS)(HTS) 시설의 수가 증가하고 있는 것도 최근 고처리량 스크리닝(HTS) 시장의 가격을 자극하고 있습니다. 이러한 센터의 중요한 장점 중 하나는 연구자, 과학자, 연구자 등 간의 지식 공유입니다. 예를 들어, Columbia Genome Center는 Columbia University의 연구자 커뮤니티에 양질의 분자 스크리닝 서비스를 제공합니다. 또한, EU-open-screen으로 알려진 미국 국립보건원(NIH)의 프로그램에 대응하는 유럽에서는 화학 생물학에 종사하는 모든 유럽 기업들에게 오픈 액세스를 제공합니다. 고처리량 스크리닝(HTS)(HTS) 센터와의 협력은 약물이나 표적 또는 전체 프로세스에 대한 유용한 정보를 제공하는 것을 목적으로 합니다. 따라서 오픈 액세스는 지식 공유를 위한 더 나은 플랫폼을 제공하고 의약품 개발 프로세스를 가속화하는 데 도움이 되기 때문에 향후 몇 년 동안 고처리량 스크리닝(HTS) 시장 점유율을 높일 수 있을 것으로 보입니다.
신규 분자 개발 증가
다양한 전염병의 유행은 새로운 분자 및 백신 개발을 촉진하고 있으며, 이는 고처리량 스크리닝(HTS) 시장에도 밝은 전망을 가져다주고 있습니다. 또한, 의약품 제조 과정에서 다양한 의약품 및 분자를 정확하고 신속하게 스크리닝해야 할 필요성이 증가함에 따라 자동화된 고처리량 스크리닝(HTS) 기술의 채택이 증가하고 있습니다. 또한, 고감도, 자동화, 시료의 최소화, 낮은 배경 신호 검출 능력 등 고처리량 스크리닝(HTS) 방법은 다양한 장점을 가지고 있어 다양한 제약사 및 생물학적 제제 회사들이 고처리량 스크리닝(HTS) 방법을 채택하는 사례가 증가하고 있으며, 이것이 고처리량 스크리닝(HTS) 시장 수요를 증가시키는 요인으로 작용하고 있습니다. 고처리량 스크리닝(HTS) 시장 수요를 증가시키고 있습니다. 미국 의회 예산국이 발표한 데이터에 따르면, 2021년 제약업계가 연구개발에 지출한 금액은 2019년 8,300만 달러에서 2020년에는 전 세계적으로 2,000억 달러에 육박할 것으로 예측됩니다. 마찬가지로 Danaher Corporation은 2020년 13억 4,800만 달러에 비해 2021년에는 17억 4,200만 달러를 연구개발에 투자할 것으로 예상했습니다. 또한, Bio-Rad Laboratories Inc.는 2020년 8억 3,000만 달러에 비해 2021년 8억 7,960만 달러를 투자했습니다. 이와 같이 기업의 R&D 투자 증가는 고처리량 스크리닝 분석에 혁신적인 기술을 채택할 수 있는 능력을 더욱 향상시켜 시장 성장을 증가시키고 있습니다.
기술 발전
최근 몇 년 동안 로봇 공학, 자동화, 데이터 분석, 소형화 등 끊임없는 기술 혁신으로 인해 고처리량 스크리닝(HTS) 기술이 크게 발전하고 있습니다. 또한, 자동화 및 로봇 공학의 발전은 HTS 워크플로우의 속도와 효율성을 광범위하게 향상시키고 있습니다. 자동화된 액체 처리 시스템, 플레이트 리더기, 로봇 플랫폼은 반복적인 작업을 높은 정밀도와 처리량으로 수행할 수 있게 되어 수작업 개입의 필요성을 줄여주고 있습니다. 또한, 다양한 주요 바이오 기업들도 R&D 활동에 투자하여 개선된 HTS 방법을 도입하고 있으며, 이는 HTS 시장의 수익을 증가시킬 것으로 예측됩니다. 예를 들어, 2024년 2월 생명과학 분석 기술의 세계 리더인 SCIEX는 SLAS 2024에서 Echo MS+ 시스템을 발표했습니다. 이 시스템은 독자적인 음향 방출 질량 분석 기술과 오픈 포트 인터페이스(OPI) 샘플링을 SCIEX ZenoTOF 7600 또는 Triple Quad 6500+ 시스템의 기능과 결합하여 견고한 고처리량 스크리닝 워크플로우를 확장합니다. 패널을 통해 정확한 정성 및 정량 결과를 제공합니다.
The global high-throughput screening market size reached USD 27.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 50.7 Billion by 2033, exhibiting a growth rate (CAGR) of 7.2% during 2025-2033. The increased adoption of 3D cell culture models, growing demand for personalized medicine screening assays, and rising application of CRISPR-based screening techniques are some of the key factors driving the market growth.
Major Market Drivers: The increasing utilization of HTS for minimizing the time required for manufacturing a drug is primarily driving the growth of the market. Furthermore, the development of new medicines for treating various life-threatening diseases is also catalyzing the demand for HTS techniques.
Key Market Trends: Integration of advanced technologies, such as artificial intelligence (AI) and machine learning (ML) with high-throughput screening to facilitate automation and fast data processing is one of the significant trends, augmenting the growth of the market.
Geographical Landscape: The high-throughput screening market forecast report has provided a detailed breakup and analysis of the market based on the region. This includes North America, Asia Pacific, Europe, Latin America, and Middle East and Africa. North America is expected to hold a significant market share in the high-throughput screening market owing to factors such as the increasing adoption of high-throughput screening, rising research and development expenditure, and the growing advances in combinatorial chemistry and the field of genomics.
Competitive Landscape: Some of the leading high-throughput screening market companies include Agilent Technologies Inc., Aurora Biomed Inc., Axxam S.p.A, Beckman Coulter Inc. (Danaher Corporation), Bio-RAD Laboratories Inc., Charles River Laboratories International Inc. Corning Incorporated, Luminex Corporation (DiaSorin), Perkinelmer Inc., Sygnature Discovery, Tecan Group Ltd., and Thermo Fisher Scientific, among many others.
Challenges and Opportunities: Challenges in the high-throughput screening market include data management complexities and the need for more physiologically relevant assay models, while opportunities lie in advancing technologies like automation, artificial intelligence, and organ-on-a-chip systems for more efficient and predictive screening processes.
Increasing Number of HTS Facilities
The development of new medicines for treating various life-threatening diseases is primarily driving the growth of the market. Furthermore, the rise in the utilization of HTS for minimizing the time required for manufacturing a drug is also contributing to the market growth. In addition to this, the escalating number of high-throughput screening (HTS) facilities is also catalyzing the high-throughput screening market's recent prices. One of the significant advantages of these centers is knowledge sharing among investigators, scientists, researchers, etc. For instance, the Columbia Genome Center offers high-quality molecular screening services for investigators throughout the Columbia University research community. Also, the European counterpart of the National Institutes of Health (NIH) program, known as EU-open-screen, provides open access to all European companies engaged in chemical biology. The association of high-throughput screening (HTS) centers is intended to provide useful information about the drug or target or the entire process. Thus, open access provides a better platform for knowledge sharing and can help accelerate the drug development process, which may drive the high-throughput screening market share in the coming years.
Rising Development of Novel Molecules
The rising prevalence of various infectious diseases is prompting the development of novel molecules and vaccines, which in turn is creating a positive outlook for the high-throughput screening market. Moreover, the escalating need for precise and quick screening of various drugs and molecules during the manufacturing of a drug is resulting in an increased adoption of automated high-throughput screening techniques. Furthermore, various pharmaceutical and biologic firms are increasingly adopting high-throughput screening methods on account of their various advantages, such as high sensitivity, automation, minimization of the sample, and the ability to detect low background signals, which is bolstering the high-throughput screening market demand. According to the data published by the Congressional Budget Office, in 2021, it was observed that pharmaceutical industries spent nearly US$ 200 Billion on research and development in 2020 globally, compared to US$ 83 Million in 2019. Similarly, Danaher Corporation invested US$ 1,742 Million in its research and development in 2021, as compared to US$ 1,348 Million in 2020. In addition, Bio-Rad Laboratories Inc. invested US$ 879.6 Million in 2021 as compared to US$ 800.3 Million in 2020. Thus, the increasing investment in research and development by the companies further increases their capabilities to adopt innovative technologies in high throughput screening assays, thereby increasing the market growth.
Technological Advancements
High-throughput screening (HTS) techniques have seen significant advancements in recent years, driven by the continuous innovations in robotics, automation, data analysis, and miniaturization. Moreover, advances in automation and robotics are extensively increasing the speed and efficiency of HTS workflows. Automated liquid handling systems, plate readers, and robotic platforms can now perform repetitive tasks with high precision and throughput, reducing the need for manual intervention. Additionally, various leading biotech companies are also investing in research and development activities to introduce improved HTS methods which are anticipated to propel the high-throughput screening market revenue. For instance, in February 2024, SCIEX, a global leader in life science analytical technologies, launched the Echo MS+ system at SLAS 2024. The system couples proprietary Acoustic Ejection Mass Spectrometry technology and Open Port Interface (OPI) sampling with the capabilities of either the SCIEX ZenoTOF 7600 or Triple Quad 6500+ system to deliver precise qualitative and quantitative results through an expanded panel of robust high-throughput screening workflows.
The high-throughput screening market overview indicates that cell-based assays are increasingly being used by various pharmaceutical and biotech companies. Cell-based assays in high-throughput screening utilize live cells as the biological readout for compound testing, enabling the evaluation of drug candidates' effects on cellular function, viability, and phenotype in a high-throughput manner, often employed in drug discovery and toxicity screening. Fluorometric imaging plate reader assays have become the most used cell-based assays owing to visible results and their ability to test with the smallest of volumes. Besides this, ultra-high-throughput screening is the latest technology and is used for increased output in less time. A majority of companies are in a transition phase from 2D-cell cultures to 3D-cell cultures as 3D cells show more lifelike properties while testing in the natural environment and other cell-related manipulations, aided for drug design and discovery.
The high-throughput screening market report has provided a detailed breakup and analysis of the market based on the products and services. This includes instruments, reagents and kits, and services.
High-throughput screening relies on specialized instruments, such as automated liquid handlers, plate readers, and robotic platforms. These instruments enable the rapid handling, dispensing, and analysis of samples in microplate formats, thereby increasing the efficiency and throughput of screening experiments. Whereas reagents and kits that are used in high-throughput screening include compound libraries, biochemical assays, and detection reagents such as fluorescent probes or enzyme substrates. These are optimized for compatibility with automated systems and miniaturized assay formats, allowing for the screening of large compound libraries against specific biological targets or pathways.
Target identification and validation involves identifying and validating molecular targets (such as proteins, genes, or cellular pathways) that are implicated in a disease or biological process. Through various methods, including genomics, proteomics, and bioinformatics, potential targets are identified and then validated to ensure their relevance and draggability for further investigation. Whereas in primary and secondary screening large libraries of compounds are tested against a specific target or biological assay to identify initial hits that show activity or modulation. This method involves a more detailed characterization of hit compounds to confirm their activity, selectivity, and potency. Primary and secondary screening typically includes dose-response studies, counter-screens, and secondary assays to validate hits and prioritize them for lead optimization and preclinical development.
According to high-throughput screening market statistics by IMARC, the spending on research and development (R&D) by both pharmaceutical companies and government organizations has been increasing recently, which is anticipated to drive market growth over the forecast period. For instance, Danaher Corporation, a leading global life sciences and diagnostics innovator, invested US$ 1,742 Million in its research and development in 2021, as compared to US$ 1,348 Million in 2020. In addition, Bio-Rad Laboratories Inc. invested US$ 879.6 Million in 2021 as compared to US$ 800.3 Million in 2020. Thus, the huge investment by pharmaceuticals, biotech firms, and government institutions will continue to drive the market growth.
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
North America is expected to hold a significant market share in the high-throughput screening market owing to various factors such as the increasing adoption of high-throughput screening, rising research and development expenditure, and the growing advances in combinatorial chemistry and the field of genomics. In addition to this, the presence of prominent market players in the region is also positively impacting the high-throughput screening market outlook. For instance, in August 2021, Becton, Dickinson, and Company launched a new, fully automated high-throughput diagnostic system using robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core laboratories and other centralized laboratories in the United States. This launch made BD Onclarity HPV Assay with extended genotyping for the BD COR System available to the high-throughput labs for processing most cervical cancer screening specimens in the United States with persistent infection with human papillomavirus (HPV).
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
April 2024: Gordian Biotechnology introduced a high-throughput in vivo screening platform to discover therapies and better predict human outcomes for age-related diseases.
April 2024: Metrion Biosciences Limited and Enamine Ltd., announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine's compound libraries.
February 2024: SCIEX, a global leader in life science analytical technologies, launched the Echo MS+ system at SLAS 2024. The system couples proprietary Acoustic Ejection Mass Spectrometry technology and Open Port Interface (OPI) sampling with the capabilities of either the SCIEX ZenoTOF 7600 or Triple Quad 6500+ system to deliver precise qualitative and quantitative results, through an expanded panel of robust high-throughput screening workflows.